Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

INTRODUCTION: Breast Cancer Prevention Trial (BCPT) and Multiple Outcomes of Raloxifene (MORE) data have been interpreted to indicate that tamoxifen reduces the risk of ER+ but not ER- breast carcinogenesis. We explored whether these data also support an alternative hypothesis, that tamoxifen influe...

Descripción completa

Detalles Bibliográficos
Autores principales: Esserman, Laura J, Ozanne, Elissa M, Dowsett, Mitch, Slingerland, Joyce M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410777/
https://www.ncbi.nlm.nih.gov/pubmed/16457695
http://dx.doi.org/10.1186/bcr1342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1410777/
https://www.ncbi.nlm.nih.gov/pubmed/16457695
http://dx.doi.org/10.1186/bcr1342

Ejemplares similares